Department of Cardiology, Austin Health, Melbourne, Victoria, Australia.
Department of Cardiology, Austin Health, Melbourne, Victoria, Australia; Department of Cardiology, Northern Health, Melbourne, Victoria, Australia; Department of Medicine, The University of Melbourne, Melbourne, Victoria, Australia.
Heart Rhythm. 2023 Aug;20(8):1178-1187. doi: 10.1016/j.hrthm.2023.05.010. Epub 2023 May 10.
Conduction system pacing (CSP)-His bundle pacing (HBP) and left bundle branch area pacing (LBBAP)-are emerging alternatives to biventricular pacing (BVP) for cardiac resynchronization therapy (CRT) in heart failure. However, evidence is largely limited to small and observational studies. We conducted a meta-analysis including a total of 15 randomized controlled trials (RCTs) and non-RCTs that compare CSP (HBP and LBBAP) with BVP in patients with CRT indications. We assessed the mean differences in QRS duration (QRSd), pacing threshold, left ventricular ejection fraction (LVEF), and New York Heart Association (NYHA) class score. CSP resulted in a pooled mean QRSd improvement of -20.3 ms (95% confidence interval [CI] -26.1 to -14.5 ms; P < .05; I= 87.1%) vs BVP. For LVEF, a weighted mean increase of 5.2% (95% CI 3.5%-6.9%; P < .05; I = 55.6) was observed after CSP vs BVP. The mean NYHA score was reduced by -0.40 (95% CI -0.6 to -0.2; P < .05; I = 61.7) after CSP vs BVP. A subgroup analysis of outcomes stratified by LBBAP and HBP demonstrated statistically significant weighted mean improvements of QRSd and LVEF with both CSP modalities compared with BVP. LBBAP resulted in NYHA improvement compared with BVP, without differences between CSP subgroups. LBBAP is associated with a significantly lowered mean pacing threshold of -0.51 V (95% CI -0.68 to -0.38 V) while HBP had increased the mean threshold (0.62 V; 95% CI -0.03 to 1.26 V) compared with BVP; however, this was associated with significant heterogeneity. Overall, both CSP techniques are feasible and effective CRT alternatives for heart failure. Further RCTs are needed to establish long-term efficacy and safety.
心脏传导系统起搏(CSP)-希氏束起搏(HBP)和左束支区域起搏(LBBAP)-是心力衰竭心脏再同步治疗(CRT)中除双心室起搏(BVP)以外的新兴替代方法。然而,证据主要局限于小型观察性研究。我们进行了一项荟萃分析,共纳入 15 项比较 CRT 适应证患者 CSP(HBP 和 LBBAP)与 BVP 的随机对照试验(RCT)和非随机对照试验。我们评估了 QRS 时限(QRSd)、起搏阈值、左心室射血分数(LVEF)和纽约心脏协会(NYHA)心功能分级评分的平均差异。与 BVP 相比,CSP 可使 QRSd 平均改善-20.3ms(95%置信区间 [CI]:-26.1 至 -14.5ms;P<.05;I=87.1%)。对于 LVEF,与 BVP 相比,CSP 后观察到加权平均增加 5.2%(95%CI:3.5%至 6.9%;P<.05;I=55.6%)。与 BVP 相比,CSP 后平均 NYHA 评分降低-0.40(95%CI:-0.6 至 -0.2;P<.05;I=61.7%)。根据 LBBAP 和 HBP 进行的结局亚组分析显示,与 BVP 相比,两种 CSP 方式的 QRSd 和 LVEF 的加权平均改善均具有统计学意义。与 BVP 相比,LBBAP 可改善 NYHA 分级,且 CSP 亚组之间无差异。与 BVP 相比,LBBAP 平均起搏阈值降低-0.51V(95%CI:-0.68 至 -0.38V),而 HBP 则使平均阈值升高(0.62V;95%CI:-0.03 至 1.26V);但存在显著异质性。总体而言,两种 CSP 技术对于心力衰竭都是可行且有效的 CRT 替代方法。需要进一步的 RCT 来确定其长期疗效和安全性。